Small-Molecule Inhibitor Drugs in Neurodegenerative Diseases
Nysa Daru
21/11/26
Neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD), are progressive disorders characterized by neuronal dysfunction and loss, resulting in cognitive, motor, and neurological decline. AD is primarily associated with the accumulation of β-amyloid plaques and hyperphosphorylated tau neurofibrillary tangles, along with oxidative stress, neuroinflammation, synaptic dysfunction, and neuronal loss. In PD, progressive degeneration of dopaminergic neurons is associated with α-synuclein aggregation, mitochondrial dysfunction, oxidative stress, impaired autophagy–lysosomal pathways, and neuroinflammation. Although current treatments provide symptomatic relief, they do not effectively halt or reverse the underlying neurodegenerative processes, emphasizing the need for disease-modifying therapeutic strategies. Small-molecule inhibitors (SMIs) have emerged as promising therapeutic candidates because of their ability to selectively modulate disease-associated proteins and molecular pathways. This review discusses the classification and mechanisms of SMIs targeting amyloidogenic processing, tau phosphorylation and aggregation, cholinergic dysfunction, α-synuclein aggregation, kinase activity, oxidative stress, neuroinflammation, mitochondrial dysfunction, and autophagy–lysosomal pathways, and evaluates the clinical evidence for their use as disease-modifying treatments (DMTs) in AD and PD. Although SMIs have theoretical advantages over biologic therapies, such as intracellular access and lower production costs, their clinical translation has been limited: only a small number of symptomatic SMIs are FDA-approved, and most disease-modifying candidates have failed to show significant clinical benefit despite successfully engaging their molecular targets. But there are obstacles such as target specificity, blood–brain barrier penetration, toxicity, and limited clinical translation that are significant to their successful development.
